Drug
Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_4
1
33%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
NCT05435209
completedphase_3
Gardasil Versus Cervarix in the Treatment of Warts
NCT05383625
completednot_applicable
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
NCT00941889
Clinical Trials (3)
Showing 3 of 3 trials
NCT05435209Phase 4
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
NCT05383625Phase 3
Gardasil Versus Cervarix in the Treatment of Warts
NCT00941889Not Applicable
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3